LDL vs. Inflammation: Debating the Drivers of Cardiovascular Risk
This video features a debate between Professor Peter Libby and Professor Derick Raal on the roles of inflammation versus LDL cholesterol lowering in cardiovascular disease risk reduction. Peter Libby argues that while LDL cholesterol is important, there is significant residual inflammatory risk even when LDL is well-controlled. He presents evidence that inflammation, particularly interleukin-6, plays a causal role in atherosclerosis and that anti-inflammatory therapies may offer additional benefit beyond lipid lowering. Libby emphasizes the need to consider multiple risk factors beyond just LDL, including inflammation, diabetes, and chronic kidney disease.
Derick Raal contends that LDL cholesterol is the primary causal factor in atherosclerosis, with inflammation being a consequence rather than a cause. He argues that more aggressive and earlier LDL lowering is needed to truly prevent cardiovascular disease, citing evidence from genetic studies and familial hypercholesterolemia. Raal acknowledges inflammation's role but believes it can be addressed primarily through lifestyle changes and weight loss rather than specific anti-inflammatory therapies. Ultimately, both speakers agree there is value in addressing both lipids and inflammation, with Libby emphasizing a multi-faceted approach and Raal prioritizing more intensive LDL reduction starting at younger ages.
▶
